Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Indivior slumps on profit warning as top-selling drug loses market share to copycat

Dr Reddy’s was only allowed to sell its generic rival to Indivior’s Suboxone drug for a matter of days but the FTSE 100 drugmaker has already seen a sharp drop-off in sales
suboxone drug
A temporary restraining order is currently preventing Dr Reddy’s from selling its version of the drug

Indivior PLC (LON:INDV) has warned sales and profits will be lower than expected this year as its star drug comes under pressure from copycat rivals.

The news sent shares in the drugmaker plunging by a third to 255.6p at the opening bell in London.

Last month, Indian giant Dr Reddy’s launched a cut-price version of Suboxone – Indivior’s blockbuster treatment for opiate drug addiction.

The FTSE 250-listed group is adamant that the generic drug infringes on some of its patents and went straight to the court asking them to prevent Dr Reddy’s from selling it while the dispute is resolved.

READ: US courts extend temporary restraining order

A temporary restraining order was granted but Indivior said it has already seen the impact from the launch of the copycat into the US market in those few days between the launch and the TRO being granted.

“The company has observed recent accelerated market share loss for Suboxone of two-and-half percentage points, to 52 percent, in the most recent weekly data,” read this morning’s statement.

“While the eventual impact could be materially higher depending on Dr Reddy's final stocking levels, Indivior currently anticipates the FY 2018 net revenue impact from this level of share loss to be US$25mln.”

Given the impact already seen and the potential for greater losses, Indivior said its current full-year guidance – net revenue of between US$1.13-1.17bn and adjusted net income of US$280-320mln – is “no longer valid”.

Indivior relies heavily on Suboxone, which makes up about four-fifths of its total annual sales.

READ: Indivior boss upbeat on Suboxone replacement prospects

To try to reduce the dependence, the drug make has launched Sublocade – an injectable version of its best-selling drug. It had hoped this would make up for some of the shortfall in Suboxone but that hasn’t been the case so far.

Indivior still has hopes for Sublocade to be a blockbuster drug in its own right but now expects sales to be around US$50mln lower than previous forecasts due to “friction in the new distribution and reimbursement model”.

Chief executive Shaun Thaxter said: “Given the swift and material change in US market dynamics as well as the early-stage reimbursement and distribution model challenges we are experiencing with Sublocade, we are removing our FY 2018 net revenue and net income guidance.

“We are continuing to monitor US market developments to better gauge Dr Reddy's launch impact.

“We know that they are skilled in rapid distribution in quantity and, as such, there is a range of uncertainty around the amount of product they were able to ship before the temporary restraining order was granted by the court.”

Thaxter added that Indivior was looking to make US$25mln worth of cost saving to mitigate the dip in sales.

View full INDV profile View Profile

Indivior Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use